This would involve supplementation with nutritional vitamin D (or calcifediol) with the goal of achieving a specific clinical benefit—such as PTH suppression, a reduction in proteinuria, or a decrease in inflammatory markers—while meticulously monitoring to prevent the onset of hypercalcemia or hyperphosphatemia. The gene discussed is PTH; the disease is hyperphosphatemia.